Insmed Inc Stock Performance
| INSM Stock | USD 102.92 0.14 0.14% |
On a scale of 0 to 100, Insmed holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of 0.74, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Insmed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Insmed is expected to be smaller as well. Please check Insmed's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Insmed's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Insmed Inc are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Insmed displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.14 | Five Day Return (1.99) | Year To Date Return 47.13 | Ten Year Return 292.52 | All Time Return (37.62) |
Last Split Factor 1:10 | Last Split Date 2011-03-03 |
1 | Disposition of 6830 shares by Lewis William of Insmed at 10.85 subject to Rule 16b-3 | 05/01/2025 |
2 | Disposition of 20000 shares by Michael Smith of Insmed at 70.0 subject to Rule 16b-3 | 05/30/2025 |
3 | Jefferies Boosts Insmed Price Target to 121 Amid Promising Data INSM Stock News | 06/10/2025 |
4 | Insmeds Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast | 06/11/2025 |
5 | Insmed Inc Soars 30 percent on Impressive Study | 06/12/2025 |
6 | Disposition of 4186 shares by Roger Adsett of Insmed at 99.32 subject to Rule 16b-3 | 06/16/2025 |
7 | Disposition of 7000 shares by Lewis William of Insmed at 98.5 subject to Rule 16b-3 | 06/18/2025 |
8 | Russell Rebalance 3 Stocks Ready to Move Higher | 06/20/2025 |
9 | Disposition of 12636 shares by Bonstein Sara of Insmed at 19.74 subject to Rule 16b-3 | 06/23/2025 |
10 | Disposition of 4362 shares by Bonstein Sara of Insmed at 24.7 subject to Rule 16b-3 | 07/07/2025 |
11 | JPMorgan Elevates Insmed Target Price Amid Positive Outlook INSM Stock News | 07/08/2025 |
12 | Disposition of 35583 shares by Bonstein Sara of Insmed at 95.66 subject to Rule 16b-3 | 07/09/2025 |
13 | 100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today | 07/11/2025 |
14 | Jim Cramer Calls Insmed Very Speculative | 07/14/2025 |
15 | Disposition of 933 shares by Michael Smith of Insmed at 102.51 subject to Rule 16b-3 | 07/15/2025 |
16 | Insmed Target Price Raised by Morgan Stanley INSM Stock News | 07/17/2025 |
17 | Disposition of 1430 shares by Lewis William of Insmed at 71.94 subject to Rule 16b-3 | 07/22/2025 |
| Begin Period Cash Flow | 482.4 M | |
| Total Cashflows From Investing Activities | -583.2 M |
Insmed Relative Risk vs. Return Landscape
If you would invest 6,896 in Insmed Inc on April 24, 2025 and sell it today you would earn a total of 3,396 from holding Insmed Inc or generate 49.25% return on investment over 90 days. Insmed Inc is currently generating 0.7392% in daily expected returns and assumes 4.2947% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Insmed, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Insmed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Insmed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Insmed Inc, and traders can use it to determine the average amount a Insmed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1721
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INSM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.74 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Insmed is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Insmed by adding it to a well-diversified portfolio.
Insmed Fundamentals Growth
Insmed Stock prices reflect investors' perceptions of the future prospects and financial health of Insmed, and Insmed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Insmed Stock performance.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (2.66) % | ||||
| Operating Margin | (2.48) % | ||||
| Current Valuation | 19.47 B | ||||
| Shares Outstanding | 189.95 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 196.89 X | ||||
| Price To Sales | 51.31 X | ||||
| Revenue | 363.71 M | ||||
| Gross Profit | 291.47 M | ||||
| EBITDA | (814.14 M) | ||||
| Net Income | (913.77 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 45.49 M | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.55 X | ||||
| Cash Flow From Operations | (683.88 M) | ||||
| Earnings Per Share | (5.93) X | ||||
| Market Capitalization | 19.55 B | ||||
| Total Asset | 2.03 B | ||||
| Retained Earnings | (4.36 B) | ||||
| Working Capital | 1.32 B | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
About Insmed Performance
By examining Insmed's fundamental ratios, stakeholders can obtain critical insights into Insmed's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Insmed is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 419.64 | 547.40 | |
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.51) | (0.48) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (3.20) | (3.04) |
Things to note about Insmed Inc performance evaluation
Checking the ongoing alerts about Insmed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Insmed Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Insmed Inc appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 363.71 M. Net Loss for the year was (913.77 M) with profit before overhead, payroll, taxes, and interest of 291.47 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (683.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Insmed Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Is Inhibrx Biosciences Inc. a good long term investment - Triple-digit returns - jammulinksnews.com |
- Analyzing Insmed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Insmed's stock is overvalued or undervalued compared to its peers.
- Examining Insmed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Insmed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Insmed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Insmed's stock. These opinions can provide insight into Insmed's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.93) | Revenue Per Share | Quarterly Revenue Growth 0.229 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.